News | December 17, 2024
Merck to acquire HUB Organoids to advance cell culture portfolio
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Harnessing advanced data analysis for early detection, prevention and better outcomes
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
For people with relapsed or refractory diffuse large B-cell lymphoma
New research labs and process development services to enable next generation therapeutics
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
